
MYELOPATHY.ORG

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2022

CONTENTS

	Page
Reference and administrative details of the charity, its Trustees and advisers	1
Trustees' report	2 - 9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Notes to the financial statements	13 - 20

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 30 JUNE 2022**

Trustees

Dr Mark Kotter
Lady Julia K H Carter of Coles
Mrs Weslie R Janeway
Ms Helen J Wood
Dr Johann Graggaber
Ms Carol Sun
Mr David Townshend
Mr Iwan Lloyd Sadler
Mr Roy Smith (appointed 6 January 2023)

Charity registered number

1178673

Principal office

Lakin Rose
Pioneer House
Vision Park
Histon
Cambridge
CB24 9NL

Independent examiners

Lakin Rose Limited
Pioneer House
Vision Park
Histon
Cambridge
CB24 9NL

**TRUSTEES' REPORT
FOR THE YEAR ENDED 30 JUNE 2022**

The Trustees present their annual report together with the financial statements of the Myelopathy.org for the year 1 July 2021 to 30 June 2022.

Objectives and activities

a. Policies and objectives

To advance health and education in all aspects of Degenerative Cervical Myelopathy (DCM) in particular but not exclusively by:

1. Supporting and funding scientific research into all aspects of DCM and ensuring the useful results of such research are publicly disseminated.
2. Raising awareness and understanding of the condition in all its forms including sharing current research and healthcare information.
3. Supporting and promoting improved physical and mental outcomes for patients including establishing support for patients, carers and health professionals.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

b. Main activities undertaken to further the charity's purposes for the public benefit

(1) Research

The following section summarises the projects that Myelopathy.org has been involved in which further our first charitable aim, to support research in the field of DCM. Below we have included further explanations of each of the projects which in each case are being done to better understand the condition and the best ways to treat it, in order to improve the lives of the people affected by it. We believe that this is for the future public benefit and fulfils our obligations as trustees.

AO Spine RECODE DCM - transition to Myelopathy.org

Myelopathy.org has continued to partner with AO Spine RECODE DCM, an international consensus initiative to involve people with DCM alongside healthcare professionals, in the design and direction of DCM research. The top 10 research priorities were identified in November 2019 (see table below) followed by a Core Outcome Set and Core Data Elements in October 2020. These outcomes are those that matter most to people living with DCM as well as those who treat them. They include life impact, economic impact, and pain and neuromuscular function. The data elements include demographics, co-morbidities, imaging and surgical details. Taken together this constitutes what to measure in all future DCM studies.

The third and final consensus meeting took place on 1 June 2022 at the Global Spine Congress in Las Vegas, Nevada, USA. The healthcare professionals of RECODE-DCM came together, with much-valued representation from people living with DCM, to decide which measurement tools to use in all DCM research going forward. Factors which were considered were the tools' quality, popularity, feasibility to use (i.e. not too onerous on the patient) and how relevant they were to the core outcomes.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2022**

Objectives and activities (continued)

The following measurement tools were selected by consensus:

- The modified Japanese Orthopaedic Association Score (mJOA)
- The SF-36 Life Impact Scale
- The Neck Disability Index
- The Spinal Adverse Events Severity System

These tools were felt to be the best options at present for a Core Measurement Set. All investigators should find opportunities to extend these assessments in their trials, depending on their research question. In addition during 2021 and 2022 the first three special interest groups were formed to drive advances in 3 of the top 10 research priorities.

The Diagnostic Criteria incubator members are working on a signs and symptoms review, to generate a solid framework for ruling DCM in and ruling it out.

The Natural History incubator members are undertaking a survey to establish current practice for asymptomatic cervical cord compression, and mild myelopathy. The survey so far has almost 600 responses.

The Peri-Operative Rehabilitation incubator members are designing the world's first and largest scoping survey to establish what rehabilitation there is at present, what the evidence is, and how we can do better.

In May 2022 Myelopathy.org entered into a 3-year transition agreement with AO Spine to ensure the efficient handover of the RECODE DCM project to Myelopathy.org.

Myelopathy.org is establishing a strategy to both fund and manage the RECODE DCM network and we are excited to work on this initiative during the next year.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2022

Objectives and activities (continued)

The Top Ten Research Priorities

	Short Title	Full Priority Wording
1	Raising Awareness	What strategies can increase awareness and understanding of DCM amongst healthcare professionals and the public? Can these strategies help improve timely diagnosis and management of DCM?
2	Natural History	What is the natural history of DCM? What is the relationship between DCM and asymptomatic spinal cord compression or canal stenosis? What factors influence the natural history of the disease?
3	Diagnostic Criteria	What are the diagnostic criteria of DCM? What is the role of imaging and when should imaging be used in the assessment of DCM?
4	Assessment and Monitoring	What assessment tools can be used to evaluate functional impairment, disability and quality of life in people with DCM? What instruments, tools or methods can be used or developed to monitor people with DCM for disease progression or improvement either before or after surgical treatment?
5	Pathophysiology	What is the pathophysiology of DCM? What are the mechanisms of neurological injury and the molecular and anatomical consequences?
6	Rehabilitation	What is the role of rehabilitation following surgery for DCM? Can structured postoperative rehabilitation improve outcome following surgery for DCM? What are the most effective strategies?
7	Novel Therapies	Can novel therapies, including stem-cell, gene, pharmacological and neuroprotective therapies, improve the health and wellbeing of people living with DCM and slow down disease progression?
8	Socio-economic Impact	What is the socio-economic impact of DCM? (<i>The financial impact of living with DCM to the individual, their supporters and society as a whole</i>)
9	Imaging Techniques	What is the role of dynamic or novel imaging techniques and neurophysiology in the assessment of DCM?
10	Individualising Surgery	Are there clinical and imaging factors that can help a surgeon select who should undergo surgical decompression in the setting of DCM? At what stage of the disease is surgery the preferred management strategy?

These research priorities will direct future Myelopathy.org funding and strategies.

RECEDE Myelopathy [Regeneration in Cervical Degenerative Myelopathy]

(University of Cambridge and National Institute for Health Research)

Phase III, double blind, placebo randomised controlled efficacy study of Ibudilast (a medicine) as an additional therapy to decompressive surgery (the gold standard treatment) for DCM. Ibudilast is a medicine currently under investigation for treatment of Multiple Sclerosis, Motoneuron Disease (ALS) and Brain Tumours. Myelopathy.org continues to support this clinical research trial. After pandemic related delays the trial recruited it's first patients in Cambridge during 2021-22.

POLYFIX-DCM

(University of Cambridge and National Institute for Health Research).

Myelopathy.org is a partner and supports this clinical trial to compare two types of surgery for DCM. We have brought the voice of people with DCM to the design of this clinical trial. Recruitment to the trial commenced during 2022.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2022**

Objectives and activities (continued)

DCM Core Information Set (COINS)

Myelopathy.org has continued to receive support by way of a grant from the Evelyn Trust to create the first comprehensive education framework for people with DCM. The aim of the project is to define key points at which people with DCM require information and the content of this. We will develop a series of Core Information Sets, 'checklists,' to help ensure professionals and people with DCM cover critical concepts at key points in their journey. This is hugely important for people with DCM and will better support shared decision making in DCM, a National Institute for Health and Care (NICE) recommendation and help to bring evidence-based care into every clinic. This will empower people with DCM to ensure their care is in-line with the latest evidence.

(2) Awareness

This section describes the activities of Myelopathy.org has been involved in that further our second charitable aim, to raise awareness of DCM.

Myelopathy.org website and branding

In April 2022, we launched our new website and rebrand of Myelopathy.org. This fresh look and improved content has had such a positive impact on all our community – making it easier to access much needed information about DCM.

In particular we would like to thank our amazing volunteers from Mu Digital who assisted with web design and development and Andrea Malaskova for her amazing illustrations.

Our website is our hub of information about the charity and also a vital resource for people with DCM and healthcare professionals.

Weekly Blog

In April 2022 in conjunction with the launch of our new website we have also introduced a weekly blog post which includes interviews with volunteers, updates from our support group and articles about DCM research. All our blogs are available to listen to as well as read as people with DCM sometimes find it more comfortable to listen to content rather than read it.

Myelopathy Matters PodCasts

Myelopathy Matters is a PodCast series produced by Myelopathy.org and series 4 was launched in 2022. The aim of the PodCast is to bring the latest information on living with, managing and understanding DCM, through expert guests from around the world.

PodCasts are a popular medium, and well suited for listeners with DCM, who may become uncomfortable sitting watching a screen for example.

Google Ads

Myelopathy.org has continued to benefit from the Google Ad Grant awarded during 2021-22. This has enabled Myelopathy.org to take advantage of the \$10,000 USD monthly budget of in-kind Google Ads advertising credit through the Google Ad Grants program.

Our Google Ads campaigns has focused on two key objectives in different geographical locations:

1. targeting aware groups
2. targeting non-aware groups

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2022**

Objectives and activities (continued)

(3) Support

Support Group

Our Myelopathy Support page on Facebook continues to grow and now has over 3,000 followers. Myelopathy.org also runs an on-line private support group on Facebook which has approximately 2100 members. There has been an increase in the number of requests to join the support group since the re-launch of the website and introduction of the weekly blogs.

This group helps to reduce isolation for our community and increases their knowledge of DCM. The group is run by volunteers, all of whom have DCM, and provides a unique space for our community to interact and engage on a one-to-one basis with people in similar circumstances. The group provides emotional support, social networks and educational resources. Members of the DCM community also run a peer mentoring programme where people with significant lived experience of DCM provide information and support to others during different stages of their DCM journey.

Both groups are led by Iwan Sadler, co-founder of Myelopathy.org and a person with DCM.

Coffee with Esther

In January 2022 a member of our support group, Esther Martin-Moore established a virtual Coffee Break meeting for people with DCM. Esther describes below why she came up with the idea.

"The coffee breaks idea was from a conversation I had with my husband. Throughout the pandemic, we would do video calls with family and friends as a group, had quizzes and caught up. But as restrictions were lifted, everyone slowly went back to their normal lives. I was once again home alone and trying to live day-by-day. I realised others must live like this. Surely they would like to chat to someone, make new friends face-to-face. So I messaged Iwan and asked if we could hold a virtual coffee break. Each coffee break gives me a boost for that day, knowing I have spoken to people that understand. We talk about all sorts of topics and offer advice, not medical advice, but on things that can help. We also talk about how we are feeling, how everyone's week has been. It's just like talking to a friend you know."

The coffee breaks have become an increasingly popular feature of the Support Group and are much appreciated by the members.

Podcasts

The Myelopathy Matters PodCast series offers the DCM community an additional platform to learn about what is happening at Myelopathy.org. The series includes information on research projects, interviews with leading healthcare professionals in the field of DCM and information from people with DCM. This helps to fulfil our objective of supporting and improving the physical and mental outcomes for people with DCM by providing a supportive and informative information source.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2022**

Achievements and performance

a. Review of activities

Below is a brief summary of the main achievements of Myelopathy.org this year.

2021-22 has been a year of organisational growth for Myelopathy.org. Following the success of the appointment of Zahabiya Karimi as a consultant during 2020-21 to assist the board to produce a strategic plan for developing the charity and subsequent fundraising, Myelopathy.org appointed our first member of staff. Zahabiya was appointed as Director of Myelopathy.org and took up the role on a part-time basis on 1 July 2021.

- **Fundraising**

Myelopathy.org held its first fundraising challenge event in 2021. 30 supporters took part in the Cambridge Half Marathon in November 2021 and raised an incredible £15,000.

We continue to receive support from the Evelyn Trust for our DCM Coins project and now also receive support from AO Spine for the RECODE -DCM project.

In addition to these we have continued to receive much needed donations from our beneficiaries and their supporters together with donations (both large and small) from other donors.

- **Volunteers**

Volunteers are key to everything we do at Myelopathy.org and we could not continue to operate without their incredible support, in particular our fantastic group of volunteers (all people with DCM) who run our support group. During 2021-22 we continued to build up a professional volunteer programme to expand our capacity. Volunteers have continued to work on the following projects; website design and re-development, charity rebranding, content for all areas of our work, general charity administration, grant writing and research, Human Resources and DCM COINS.

- **Operations, outreach, and communication**

During 2021-22 we have continued working on Myelopathy.org's compliance which has included putting additional policies in place to cover Equalities and Diversity, Safeguarding, On-line safety, Maternity and Parental Leave and Complaints.

In April 2022 we completed and launched our new website (both design and content) and charity re-brand and introduced a weekly blog post.

- **Programmes**

We have continued to be a partner in RECODE-DCM and in May 2022 Myelopathy.org entered into a 3-year transition agreement with AO Spine to ensure the efficient handover of the RECODE DCM project to Myelopathy.org.

Myelopathy.org is establishing a strategy to both fund and manage the RECODE DCM network and we are excited to work on this initiative during the next year.

We have continued work on the DCM COINS project to create the first comprehensive education framework for people with DCM.

We have continued to partner NIHR funded clinical trials to bring the voice of people with DCM to these trials.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2022**

Achievements and performance (continued)

We have continued to develop and broadcast our Myelopathy Matters PodCast series to better inform our community about the work of Myelopathy.org.

Financial review

a. Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

b. Reserves policy

At present Myelopathy.org has minimal annual liabilities. Consequently, and based on the limited annual income, it is felt that a reserve fund is not required nor possible at this time.

This position will be reviewed annually by the Trustees.

Structure, governance and management

a. Constitution

Myelopathy.org is a registered charity, number 1178673, and was incorporated on 6 June 2018.

b. Methods of appointment or election of Trustees

The management of the charity is the responsibility of the Trustees who are elected and co-opted under the terms of the Constitution.

c. Financial risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

Members' liability

The Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2022**

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on **22 April 2023** and signed on their behalf by:

Ms Helen J Wood
Trustee

HJ Wood

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 30 JUNE 2022**

Independent Examiner's Report to the Trustees of Myelopathy.org ('the charity')

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 30 June 2022.

Responsibilities and Basis of Report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Your attention is drawn to the fact that the charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

We understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our work or for this report.

Signed:



Dated: 24 April 2023

C P J Dougherty FCA

Lakin Rose Limited

Pioneer House, Vision Park, Histon, Cambridge, CB24 9NL

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 30 JUNE 2022**

	Note	Restricted funds 2022 £	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Income from:					
Donations	3	4,524	74,829	79,353	118,317
Charitable activities	4	-	2,252	2,252	4,946
Investments	5	-	3	3	21
Total income		4,524	77,084	81,608	123,284
Expenditure on:					
Raising funds	6	-	3,785	3,785	1,842
Charitable activities		8,618	69,939	78,557	73,512
Total expenditure		8,618	73,724	82,342	75,354
Net movement in funds		(4,094)	3,360	(734)	47,930
Reconciliation of funds:					
Total funds brought forward		4,094	52,329	56,423	8,493
Net movement in funds		(4,094)	3,360	(734)	47,930
Total funds carried forward		-	55,689	55,689	56,423

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 13 to 20 form part of these financial statements.

MYELOPATHY.ORG

BALANCE SHEET
AS AT 30 JUNE 2022

	Note		2022 £	2021 £
Current assets				
Debtors	11	3,044	7,237	
Cash at bank and in hand		54,885	54,261	
		<u>57,929</u>	<u>61,498</u>	
Creditors: amounts falling due within one year	12	(2,240)	(5,075)	
Net current assets			55,689	56,423
Total net assets			55,689	56,423
			<u><u>55,689</u></u>	<u><u>56,423</u></u>
Charity funds				
Restricted funds	13	-	-	4,094
Unrestricted funds	13	55,689	52,329	
Total funds			55,689	56,423
			<u><u>55,689</u></u>	<u><u>56,423</u></u>

The financial statements were approved and authorised for issue by the Trustees on
22 April 2023 and signed on their behalf by:

Ms Helen J Wood
Trustee

HJ Wood

The notes on pages 13 to 20 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022**

1. General information

The charity is a charitable incorporated organisation (CIO). The charity's address is c/o Lakin Rose, Pioneer House, Vision Park, Histon, Cambridge, CB24 9NL.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Myelopathy.org meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022**

2. Accounting policies (continued)

2.3 Expenditure (continued)

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

2.4 Liabilities and provisions

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the statement of financial activities as a finance cost.

2.5 Pensions

The charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the charity to the fund in respect of the year.

2.6 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022

3. Income from donations

	Restricted funds 2022 £	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Donations	-	73,829	73,829	106,229
Grants	4,524	1,000	5,524	12,088
	<u>4,524</u>	<u>74,829</u>	<u>79,353</u>	<u>118,317</u>
Total 2021	<u>12,088</u>	<u>106,229</u>	<u>118,317</u>	

4. Income from charitable activities

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Research services	<u>2,252</u>	<u>2,252</u>	<u>4,946</u>

5. Investment income

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Interest receivable	<u>3</u>	<u>3</u>	<u>21</u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022

6. Expenditure on raising funds

Costs of raising voluntary income

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Costs of raising voluntary income	3,785	3,785	1,842

7. Analysis of expenditure by activities

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £	Total funds 2021 £
Charitable activities	2,695	75,862	78,557	73,512
Total 2021	5,964	67,548	73,512	

Analysis of direct costs

	Charitable activities 2022 £	Total funds 2022 £	Total funds 2021 £
Education	2,538	2,538	3,095
Research	157	157	2,869
	2,695	2,695	5,964

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022**

7. Analysis of expenditure by activities (continued)

Analysis of support costs

	Charitable activities 2022 £	Total funds 2022 £	<i>Total funds 2021 £</i>
Staff costs	14,291	14,291	-
General office expenses	584	584	71
Computer expenses	1,000	1,000	768
Insurance	426	426	398
Subscriptions	194	194	157
Travel and subsistence	72	72	-
Grant funded Google advertisements	49,920	49,920	50,519
Consultancy	8,115	8,115	14,375
Governance costs	1,260	1,260	1,260
	<u>75,862</u>	<u>75,862</u>	<u>67,548</u>

8. Independent examiner's remuneration

The independent examiner's remuneration amounts to an independent examiner fee of £1,260 (2021 - £1,200).

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022

9. Staff costs

	2022 £	2021 £
Wages and salaries	13,581	-
Contribution to defined contribution pension schemes	710	-
	<u>14,291</u>	<u>-</u>

The average number of persons employed by the charity during the year was as follows:

	2022 No.	2021 No.
Management	<u>1</u>	<u>-</u>

No employee received remuneration amounting to more than £60,000 in either year.

10. Trustees' remuneration and expenses

During the year ended 30 June 2022, no Trustees received any remuneration or other benefits (2021 - £NIL).

During the year ended 30 June 2022, no Trustee expenses have been incurred (2021 - £NIL).

11. Debtors

	2022 £	2021 £
Trade debtors	2,252	-
Prepayments and accrued income	167	149
Tax recoverable	625	5,000
Grants receivable	-	2,088
	<u>3,044</u>	<u>7,237</u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022

12. Creditors: Amounts falling due within one year

	2022 £	2021 £
Trade creditors	1,040	1,875
Accruals and deferred income	1,200	3,200
	<u>2,240</u>	<u>5,075</u>

13. Statement of funds

Statement of funds - current year

	Balance at 1 July 2021 £	Income £	Expenditure £	Balance at 30 June 2022 £
Unrestricted funds				
General Funds	<u>52,329</u>	<u>77,084</u>	<u>(73,724)</u>	<u>55,689</u>
Restricted funds				
Facing Myelopathy Together	<u>4,094</u>	<u>-</u>	<u>(4,094)</u>	<u>-</u>
DCM COINS Project	<u>-</u>	<u>4,524</u>	<u>(4,524)</u>	<u>-</u>
	<u>4,094</u>	<u>4,524</u>	<u>(8,618)</u>	<u>-</u>
Total of funds	<u><u>56,423</u></u>	<u><u>81,608</u></u>	<u><u>(82,342)</u></u>	<u><u>55,689</u></u>

Facing Myelopathy Together Fund

This fund relates to a grant from Awards for All (part of National Lottery) which is towards staff costs and website costs.

DCM COINS Project

This fund relates to a grant receivable from Evelyn Trust to support this project. A detailed description of this project can be found in the trustees' report.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2022

13. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 July 2020 £	Income £	Expenditure £	Balance at 30 June 2021 £
Unrestricted funds				
General Funds	8,493	111,196	(67,360)	52,329
Restricted funds				
Facing Myelopathy Together	-	10,000	(5,906)	4,094
DCM COINS Project	-	2,088	(2,088)	-
	-	12,088	(7,994)	4,094
Total of funds	8,493	123,284	(75,354)	56,423

Facing Myelopathy Together Fund

This fund relates to a grant from Awards for All (part of National Lottery) which is towards staff costs and website costs.

DCM COINS Project

This fund relates to a grant receivable from Evelyn Trust to support this project. A detailed description of this project can be found in the trustees' report.